Remix Therapeutics Appoints Michael Landsittel to Board of Directors

WATERTOWN, Mass., Oct. 06, 2026 /CourierPR/ -- Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing, has appointed Michael Landsittel to its Board of Directors. The addition of Landsittel is seen as a significant step in the company’s strategic direction as it prepares to operate as a public entity.

Pete Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics, expressed enthusiasm about the appointment.

Landsittel brings extensive experience in the biotechnology sector to the board. With over 20 years of experience, he has held various roles in strategic finance, corporate and business development, investor relations, and organizational leadership. Most recently, he served as Chief Financial Officer at Blueprint Medicines Corporation, where he played a crucial role in guiding the company through its $9.1 billion acquisition by Sanofi in 2025. During his tenure at Blueprint, Landsittel led efforts to raise approximately $4 billion in capital through a variety of transactions and helped transform the company into a commercial-stage biotechnology entity with the launch of AYVAKIT® (avapritinib).

Prior to Blueprint, Landsittel held financial planning, business development, and corporate strategy roles at Algeta ASA, Infinity Pharmaceuticals, and Genzyme Corporation. Currently, he serves on the Board of Directors at Damora Therapeutics. Landsittel holds an M.B.A. from the Tuck School of Business at Dartmouth College and a B.B.A. from the University of Michigan.

Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. The company's REMaster™ technology platform leverages data science, biomolecular sciences, and chemistry approaches to identify orally administered compounds that modulate gene expression. One of the company's key projects, REM-422, an investigational small molecule designed to modulate RNA processing in oncology, is currently being evaluated in two clinical programs: the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).